| Ocular Hypertension
Alphagan P vs Durysta
Side-by-side clinical, coverage, and cost comparison for ocular hypertension.Deep comparison between: Alphagan P vs Durysta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDurysta has a higher rate of injection site reactions vs Alphagan P based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Durysta but not Alphagan P, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Alphagan P
Durysta
At A Glance
Ophthalmic
Three times daily
Alpha-2 adrenergic receptor agonist
Intracameral implant
Single dose
Prostaglandin analog
Indications
- Glaucoma, Open-Angle
- Ocular Hypertension
- Glaucoma, Open-Angle
- Ocular Hypertension
Dosing
Glaucoma, Open-Angle, Ocular Hypertension One drop in the affected eye(s) three times daily, approximately 8 hours apart; if used with other topical ophthalmic products, instill at least 5 minutes apart.
Glaucoma, Open-Angle, Ocular Hypertension Single biodegradable intracameral implant (10 mcg bimatoprost) administered once into the anterior chamber under aseptic conditions; do not readminister to a previously treated eye.
Contraindications
- Neonates and infants (pediatric patients younger than 2 years old)
- Previous hypersensitivity reaction to any component of ALPHAGAN P
- Active or suspected ocular or periocular infections
- Corneal endothelial cell dystrophy (e.g., Fuchs' Dystrophy)
- Prior corneal transplantation or endothelial cell transplants (e.g., DSAEK)
- Absent or ruptured posterior lens capsule (risk of implant migration into the posterior segment)
- Hypersensitivity to bimatoprost or any other component of the product
Adverse Reactions
Most common (>=10%) Allergic conjunctivitis, conjunctival hyperemia, eye pruritus
Serious Potentiation of vascular insufficiency, severe cardiovascular disease
Postmarketing Bradycardia, depression, hypersensitivity, iritis, keratoconjunctivitis sicca, miosis, nausea, skin reactions, syncope, tachycardia
Most common (>=5%) Conjunctival hyperemia (27%), foreign body sensation, eye pain, photophobia, conjunctival hemorrhage, dry eye, eye irritation, increased IOP, corneal endothelial cell loss, blurred vision, iritis, headache
Serious Implant migration, hypersensitivity, corneal adverse reactions, macular edema, intraocular inflammation, pigmentation, endophthalmitis
Postmarketing Endophthalmitis
Pharmacology
Brimonidine tartrate is a relatively selective alpha-2 adrenergic receptor agonist that lowers intraocular pressure by reducing aqueous humor production and increasing uveoscleral outflow, with a peak ocular hypotensive effect at approximately 2 hours post-dosing.
Bimatoprost is a prostaglandin analog with ocular hypotensive activity that lowers IOP by increasing aqueous humor outflow through both the trabecular meshwork (conventional) and uveoscleral (unconventional) routes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Alphagan P
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
Durysta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Alphagan P
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Durysta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Alphagan P
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Durysta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Alphagan P.
$0/fillfill
Durysta CoPay Assistance ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Alphagan PView full Alphagan P profile
DurystaView full Durysta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.